AlloMEK Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.67M

AlloMEK Therapeutics General Information

Description

Developer of targeted therapeutics intended to treat rare and debilitating diseases. The company's therapeutics include kinase inhibitors that improve the biopharmaceutical properties of previous inhibitors and can be used as a single agent and in combination with other treatment options, enabling physicians to provide an improved clinical response for unusual illnesses.

Contact Information

Website
www.allomek.com
Formerly Known As
AlloStem Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Research Drive
  • Woodbridge, CT 06525
  • United States
Primary Industry
Biotechnology
Corporate Office
  • 4 Research Drive
  • Woodbridge, CT 06525
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlloMEK Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 11-Oct-2022 $5.67M Completed Generating Revenue
6. Later Stage VC 10-Feb-2020 Completed Generating Revenue
5. Accelerator/Incubator 02-Feb-2018 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2016 Completed Generating Revenue
3. Seed Round 13-Mar-2015 Completed Generating Revenue
2. Seed Round 22-Apr-2013 $220K $370K Completed Startup
1. Seed Round 21-Feb-2011 $150K $150K Completed Startup
To view AlloMEK Therapeutics’s complete valuation and funding history, request access »

AlloMEK Therapeutics Patents

AlloMEK Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2534358-T3 Innovative mek inhibitors useful in the treatment of diseases Active 13-Oct-2009
US-9034861-B2 Mek inhibitors useful in the treatment of diseases Active 13-Oct-2009
US-20150250762-A1 Novel mek inhibitors for treating cardiomyopathies and related conditions Inactive 13-Oct-2009
JP-2013507453-A Novel mek inhibitors useful for the treatment of diseases Active 13-Oct-2009
JP-5892612-B2 Novel mek inhibitors useful for the treatment of diseases Active 13-Oct-2009 C07D291/08
To view AlloMEK Therapeutics’s complete patent history, request access »

AlloMEK Therapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Accelerator for Biosciences in Connecticut Accelerator/Incubator
Connecticut Innovations Venture Capital Minority
Fundación Andrés Marcio Not-For-Profit Venture Capital Minority
Angel (individual) Minority
University of Connecticut Technology Incubation Program Accelerator/Incubator
To view AlloMEK Therapeutics’s complete investors history, request access »

AlloMEK Therapeutics FAQs

  • When was AlloMEK Therapeutics founded?

    AlloMEK Therapeutics was founded in 2011.

  • Where is AlloMEK Therapeutics headquartered?

    AlloMEK Therapeutics is headquartered in Woodbridge, CT.

  • What industry is AlloMEK Therapeutics in?

    AlloMEK Therapeutics’s primary industry is Biotechnology.

  • Is AlloMEK Therapeutics a private or public company?

    AlloMEK Therapeutics is a Private company.

  • What is the current valuation of AlloMEK Therapeutics?

    The current valuation of AlloMEK Therapeutics is .

  • What is AlloMEK Therapeutics’s current revenue?

    The current revenue for AlloMEK Therapeutics is .

  • How much funding has AlloMEK Therapeutics raised over time?

    AlloMEK Therapeutics has raised $1.73M.

  • Who are AlloMEK Therapeutics’s investors?

    Accelerator for Biosciences in Connecticut, Connecticut Innovations, Fundación Andrés Marcio, , and University of Connecticut Technology Incubation Program have invested in AlloMEK Therapeutics.

  • When was AlloMEK Therapeutics acquired?

    AlloMEK Therapeutics was acquired on 11-Oct-2022.

  • Who acquired AlloMEK Therapeutics?

    AlloMEK Therapeutics was acquired by Pasithea Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process